02078nas a2200361   4500000000100000008004100001260001300042653001500055653001000070653004300080653001600123653001200139653001900151653001900170653003000189653001100219653001100230653001400241653001200255653000900267653001600276653001300292653001300305653001200318100001400330700001000344700001300354245009500367300001100462490000700473520122200480022001401702       1992                            d  c1992 Aug10aAdolescent10aAdult10aChemical and Drug Induced Liver Injury10aClofazimine10aDapsone10aDrug Eruptions10aDrug Synergism10aDrug Therapy, Combination10aFemale10aHumans10aIncidence10aleprosy10aMale10aMiddle Aged10aRifampin10aSyndrome10aVanuatu1 aReeve P A1 aAla J1 aHall J J00aDapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy.  a266-700 v953 a<p>Side-effects of leprosy treatment with dapsone are said to be uncommon, with drug allergy occurring in only one of every several hundred patients treated with dapsone. The dapsone or sulphone syndrome (DDS) has been recognized since the earliest days of sulphone therapy but until recently its incidence had been decreasing. In Vanuatu, during the years 1988-1991, nine leprosy patients have developed the dapsone syndrome, four of whom have died. During the last 4 years only 37 patients were started on treatment, which is an incidence of the dapsone syndrome of 24% with a fatality rate of 11%. All the patients were being given multi-drug treatment (MDT) of daily dapsone (100 mg) and clofazimine (50 mg) and monthly rifampicin (600 mg) and clofazimine (300 mg). There has been speculation that the increased incidence of what was previously described as a rare reaction is due to the use of MDT, and the reasons for this are discussed. We feel the increase in the number of reactions in Vanuatu since starting MDT is probably due to the high starting dose of 100 mg of dapsone, possibly enhanced by the combination with clofazimine and rifampicin and a genetic susceptibility of the Melanesian population.</p>  a0022-5304